Last reviewed · How we verify
Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients
Approved treatments
- Vistide · Gilead Sciences
- Foscavir · Clinigen Hlthcare
Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA. - Vistide · Gustave Roussy, Cancer Campus, Grand Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients patent landscape — cliff calendar, originator estates, attackable patents
- Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients treatment landscape brief
- Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients treatment updates RSS
Frequently asked questions about Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients
What drugs treat Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients?
Tracked treatments include Vistide, Foscavir.
What is the treatment for Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients?
Standard treatment for Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients includes Vistide, Foscavir. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients patent cliff · Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients CI report
- Treatment: Vistide · Gilead Sciences
- Treatment: Foscavir · Clinigen Hlthcare
- Treatment: Vistide · Gustave Roussy, Cancer Campus, Grand Paris
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing